CA3006291A1 - Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease - Google Patents

Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease Download PDF

Info

Publication number
CA3006291A1
CA3006291A1 CA3006291A CA3006291A CA3006291A1 CA 3006291 A1 CA3006291 A1 CA 3006291A1 CA 3006291 A CA3006291 A CA 3006291A CA 3006291 A CA3006291 A CA 3006291A CA 3006291 A1 CA3006291 A1 CA 3006291A1
Authority
CA
Canada
Prior art keywords
treatment
alx
fpr2
compound
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3006291A
Other languages
English (en)
French (fr)
Inventor
Jacek Ostrowski
Ricardo Garcia
Nicholas R. Wurtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA3006291A1 publication Critical patent/CA3006291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3006291A 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease Abandoned CA3006291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
US62/259,498 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (1)

Publication Number Publication Date
CA3006291A1 true CA3006291A1 (en) 2017-06-01

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3006291A Abandoned CA3006291A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Country Status (13)

Country Link
US (1) US20180325869A1 (https=)
EP (1) EP3380091A1 (https=)
JP (1) JP2018538367A (https=)
KR (1) KR20180081528A (https=)
CN (1) CN108348479A (https=)
AU (1) AU2016359463A1 (https=)
BR (1) BR112018010155A8 (https=)
CA (1) CA3006291A1 (https=)
EA (1) EA201891007A1 (https=)
IL (1) IL259468A (https=)
MX (1) MX2018005756A (https=)
SG (1) SG11201803816RA (https=)
WO (1) WO2017091496A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6811241B2 (ja) 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3634958B1 (en) * 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
CA3185263A1 (en) 2020-07-09 2022-01-13 James A. Johnson Pyrazolone formyl peptide 2 receptor agonists
KR20230051525A (ko) 2020-08-12 2023-04-18 브리스톨-마이어스 스큅 컴퍼니 옥소피롤리딘 우레아 fpr2 효능제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903378B (zh) * 2007-12-18 2014-03-12 埃科特莱茵药品有限公司 氨基三唑衍生物
CN103221392B (zh) * 2010-11-17 2015-06-03 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物
CA2871334A1 (en) * 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
JP6811241B2 (ja) * 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
KR102803660B1 (ko) * 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제

Also Published As

Publication number Publication date
JP2018538367A (ja) 2018-12-27
US20180325869A1 (en) 2018-11-15
WO2017091496A1 (en) 2017-06-01
BR112018010155A8 (pt) 2019-02-26
BR112018010155A2 (pt) 2018-11-21
EA201891007A1 (ru) 2018-11-30
KR20180081528A (ko) 2018-07-16
MX2018005756A (es) 2018-08-01
SG11201803816RA (en) 2018-06-28
AU2016359463A1 (en) 2018-07-12
CN108348479A (zh) 2018-07-31
EP3380091A1 (en) 2018-10-03
IL259468A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CA3006291A1 (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
US11873266B2 (en) Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke
JP5707489B2 (ja) １型糖尿病の処置
JP7508496B2 (ja) 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
US20200069644A1 (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
AU2014262764B2 (en) Radiomitigating pharmaceutical formulations
KR102354243B1 (ko) 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법
EA018898B1 (ru) Способ лечения амилоидоза
AU2017342551B2 (en) Methods of treatment and pharmaceutical compositions using BCN057 or BCN512
PT1587584E (pt) Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais
JP6688503B2 (ja) 医薬用組成物
JP2018537522A (ja) 組合せ
US20230114408A1 (en) Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists
KR20220143059A (ko) 섬유증의 치료를 위한 시클로스포린 유사체의 용도
US10799511B2 (en) Methods for reducing or ameliorating mortality and/or morbidity due to chlorine inhalation
WO2026064493A1 (en) Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure
WO2026057747A1 (en) Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
HK40080138A (en) Methods of modulating t-cell activation using carboranes and carborane analogs
CN115515580A (zh) 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831